Supriya Lifescience Q3 FY26 Earnings Call Transcript Released
Supriya Lifescience reported Q3 FY26 revenue of ₹206 crore, up 11% YoY, with EBITDA at ₹72 crore and PAT at ₹50 crore. The company reaffirmed its guidance of ~20% annual revenue growth and 33-35% EBITDA margins, targeting ₹1,000 crore revenue by FY27. The Ambernath facility will be capitalized in Q4 FY26.
The announcement provides an update on financial results and future outlook, including growth targets and facility capitalization, which are material for investors and indicate the company's strategic direction and performance.
The company reported year-on-year revenue growth, maintained strong EBITDA and PAT margins, and reiterated positive future growth guidance and targets, indicating a positive financial performance and outlook.
Supriya Lifescience Limited has released the transcript of its earnings call held on February 10, 2026, concerning the unaudited financial results for the quarter and nine months ended December 31, 2025. The transcript is available on the company's website and the stock exchanges. During the call, the company reported revenue of ₹206 crore for Q3 FY26, an 11% year-on-year increase, driven by robust demand. EBITDA stood at ₹72 crore with a margin of 35%, and PAT was ₹50 crore with a margin of 24.1%. For the nine months ended December 31, 2025, revenue was ₹551 crore and EBITDA was ₹196 crore. The company reiterated its guidance of approximately 20% annual revenue growth and EBITDA margins of 33% to 35%, with a target of ₹1,000 crore revenue for FY27. The Ambernath facility is slated for capitalization in Q4 FY26. New product launches, including a cardiovascular product and an ADHD product, are progressing as planned and are expected to contribute significantly in the upcoming quarters. The company also highlighted its focus on regulated markets and backward integration, with 74% of revenues already backward integrated.
What to do with a filing like this
Supriya Lifescience Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Supriya Lifescience Limited. Read the original for the full detail.